Bluyssen HA, Rastmanesh MM, Tilburgs C, Jie K, Wesseling S, Goumans M, Boer P, Joles JA, Braam B. IFN␥-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. Am J Physiol Cell Physiol 299: C354 -C362, 2010. First published May 19, 2010 doi:10.1152/ajpcell.00513.2009.-IL-6 has proand anti-inflammatory effects and is involved in endothelial cell (EC) dysfunction. The anti-inflammatory effects of IL-6 are mediated by signal transducer and activator of transcription-3 (STAT3), which is importantly controlled by suppressor of cytokine signaling 3 (SOCS3). Therefore, cytokines that modulate SOCS3 expression might inhibit the anti-inflammatory effects of IL-6. We hypothesized that in EC, interferon-␥ (IFN␥)-induced SOCS3 expression leads to inhibition of IL-6-induced STAT3 activation and IL-6-dependent expression of anti-, but not pro-inflammatory, target genes. IFN␥ activated STAT1 and STAT3 and increased SOCS3 expression in EC. IL-6 only activated STAT3 and induced SOCS3 expression. IFN␥ pretreatment of EC inhibited IL-6-induced STAT3 activation accompanied by increased SOCS3 protein. Inhibition of SOCS3 expression, using costimulation, Act-D, and small interfering RNA (siRNA), subsequently implicated the importance of IFN␥-induced SOCS3 in this phenomenon. Pretreatment of EC with IFN␥ also affected the transcriptional program induced by IL-6. We identified 1) IL-6 antiinflammatory target genes that were inhibited by IFN␥, 2) IFN␥-target genes of pro-inflammatory nature that were increased in response to IL-6 in the presence of IFN␥, and 3) a set of target genes that were increased upon IL-6 or IFN␥ alone, or combined IFN␥ and IL-6. In summary, by increasing SOCS3 expression in EC, IFN␥ can selectively inhibit STAT3-dependent IL-6 signaling. This in turn leads to decreased expression of some EC protective genes. In contrast, other genes of pro-inflammatory nature are not inhibited or even increased. This IFN␥-induced shift in IL-6 signaling to a pro-inflammatory phenotype could represent a novel mechanism involved in EC dysfunction.
step in atherosclerosis development (34) . It has been reported that increased plasma IL-6 is related to endothelial dysfunction and atherosclerosis development (26, 34, 35) . IL-6 can have pro-and anti-inflammatory as well as pro-and anti-atherogenic effects (1, 17, 32, 42) . However, the signaling cascade of IL-6 in endothelial cells and its possible pro-or anti-inflammatory effects in endothelial dysfunction are incompletely defined.
In many atherogenic states (such as renal dysfunction) IL-6 is often increased together with other cytokines, including interferon-␥ (IFN␥) that could affect IL-6 signaling and its biological effects (14, 20) . IL-6 and IFN␥ share important intracellular signaling molecules and induce partially overlapping sets of genes (45) . Upon binding to their cognate receptors, IFN␥ and IL-6 activate Jak1 and Jak2 from the Janus kinase family (11, 33) , which terminate in activation of signal transducer and activator of transcription (STAT)1 and STAT3 in different cell types (2, 16) . However, STAT1 is the main transcription factor in IFN␥ signaling (21, 38) and STAT3 in IL-6 signaling (18) , which could explain the differences in IFN␥ and IL-6 functions (7, 36) . In vivo studies indicate that IFN␥-induced STAT1 activation is predominantly inhibited by SOCS1 and IL-6-induced STAT3 activation by SOCS3 in a negative feedback fashion (6) .
Based on previous studies, IL-6 can have anti-inflammatory effects on activated macrophages by dampening cytokine production (1, 42) . Interestingly, in the absence of SOCS3, IL-6 has much stronger anti-inflammatory effects on macrophages and hepatocytes, which is related to prolonged IL-6-induced STAT3 activation (43) . Moreover, several inflammatory signals, including IFN␥, LPS, IL-10, and IL-6, can inhibit IL-6 STAT3 signaling (that is accompanied by increased SOCS3 expression) (3, 19, 28) . Furthermore, a study by Costa-Pereira et al. (5) indicates that in STAT3 knock-out fibroblasts, IL-6 signals through STAT1 and has IFN␥-like effects.
Together, this strongly suggests that the presence of SOCS3, which could be induced by other inflammatory cytokines, importantly determines to what extent IL-6 has anti-inflammatory effects via activation of STAT3 or pro-inflammatory effects (possibly through STAT1). However, in endothelial cells it is not clear whether IFN␥ can interfere with IL-6-induced STAT3 activation, if this is related to SOCS3, and how this might affect the IL-6 target genes.
The present study was therefore initiated to test the hypothesis that, depending on the presence or absence of IFN␥, IL-6 can induce expression of pro-as well as anti-inflammatory genes in endothelial cells. We specifically addressed whether in endothelial cells IFN␥ inhibits IL-6-induced STAT3 activation in a SOCS3-dependent fashion and if this preferentially leads to inhibition of IL-6-induced expression of anti-but not pro-inflammatory target genes.
MATERIALS AND METHODS
Reagents and cell culture. Human microvascular endothelial cells (HMEC) were generously provided by Centers for Disease Control and Prevention (Atlanta, GA). Recombinant IFN␥ and IL-6 were purchased from Sigma (St. Louis, MO). Rabbit polyclonal antibodies P-Tyr (701) STAT1, and mouse antibody to P-Tyr (705) STAT3, goat polyclonal antibody to SOCS3, and horseradish peroxidase (HRP)-conjugated antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal antibodies to STAT1 and STAT3 were purchased from BD Biosciences (Franklin Lakes, NJ). Generally, 1 day before an experiment, the MCDB-131 (Invitrogen; Carlsbad, CA) medium supplemented with 1% penicillin-streptomycin, 0.1% human epidermal growth factor (hEGF), 0.1% hydrocortisone, 5% L-glutamine, and 10% fetal calf serum (FCS) (Invitrogen) was replaced with MCDB-131 containing 0.5% FCS and 1% penicillin-streptomycin. However, in small interfering RNA (siRNA) experiments HMEC were transfected with siRNA or not; received serumfree MCDB-131 1 h before cytokine stimulation. For the siRNA experiments we used siRNA of Dharmacon (Lafayette, CO), including that of transfection reagent DharmaFECT (catalog no. T-2001-02) and predesigned SMARTpool siRNA for GAPDH (catalog no. 001830-10), SOCS3 (catalog no. L-004299-00), and a mix of four nonmatched siRNA sequences (catalog no. D-001810-10).
Western analysis. Total cell extracts (15 g protein for STAT or 50 g for SOCS) from untreated and treated HMEC were electrophoresed on a 4 -20% precast acrylamide gradient gel (Cambrex; East Rutherford, NJ) or 10% acrylamide gel (for SOCS) and transferred to nitrocellulose membrane. After being blocked in ECL-blocking buffer, the membrane was either incubated with polyclonal antibodies for P-Tyr STAT1 and 3 (1:1,000) or SOCS3 (1/500). After being washed three times with phosphate-buffered saline-Tween (PBST), the membrane was incubated with goat anti-mouse, goat anti-rabbit, or rabbit anti-goat HRP-conjugated (1:1,000) antibody. Next, the membrane was washed two times with PBST and once with PBS, and bound proteins were detected with enhanced chemoluminescence (ECL, Amersham; Piscataway, NJ). The membrane was then stripped, blocked, and incubated with specific monoclonal antibodies for STAT1 and STAT3 (1:5,000) to measure the total amount of STAT proteins. The intensity of each band was quantified by using Quantity One program (Bio-Rad; Hercules, CA) and normalized on the level of STAT proteins. Results are expressed as means (P-STAT/STAT or SOCS3/ STAT3) Ϯ SD of at least six independent experiments. siRNA. HMEC were plated on fibronectin-coated six-well plates (5 ϫ 10 5 cells/well) and incubated at 37°C with 5% CO2. Subconfluent cells were transfected with siRNA (50 nM) by using Dharma-FECT1 (2 l/ml) (Dharmacon) in serum-and antibiotics-free medium. Transfection efficiency was tested and optimized by using Cy3 probe (data not shown). siRNA against GAPDH was used as a positive control and to optimize the system, which resulted in 80% reduction in GAPDH mRNA expression (data not shown). Off-target effect was tested by using a mix of four unmatched sequences of siRNA to ensure the selectivity and specificity of the siRNA system (data not shown). HMEC were stimulated with IFN␥ (1 ng/ml), IL-6 (50 U/ml), or both 48 h posttransfection with siRNA against SOCS3.
Experimental design for STAT activation and SOCS expression. A time-course study for IFN␥ and IL-6 was carried out by stimulation of HMEC with IFN␥ (1 ng/ml) or IL-6 (20 U/ml) for 0 -6 h.
A dose-response study for IFN␥ or IL-6 was performed by stimulation of HMEC with 0 -5 ng/ml IFN␥ or 0 -50 U/ml IL-6 for 30 or 120 min (data not shown).
The effect of IFN␥ on IL-6 signaling was studied by incubation of HMEC with IFN␥ (1 ng/ml) for 2 h before IL-6 (20 or 50 U/ml) stimulation for 30 or 60 min.
The role of SOCS in cross-talk between IFN␥ and IL-6 was determined by: 1) costimulation of HMEC with IFN␥ (1 ng/ml) and IL-6 (50 U/ml) for 30 min; 2) by pretreatment of HMEC with actinomycin-D (Act-D; 10 g/ml) for 15 min before stimulation with IFN␥ (1 ng/ml; 2 h) and IL-6 (50 U/ml; 30 or 60 min), and 3) knockdown of SOCS3 by siRNA before (48 h) stimulation with IFN␥ (1 ng/ml; 2h) and IL-6 (50 U/ml; 30 min).
Experimental design for microarray studies. To characterize endothelial cell transcriptomes modulated by IL-6, IFN␥, or IL-6 following IFN␥ pretreatment, four conditions were tested: 1) HMEC cells left untreated, 2) HMEC cells were treated with IFN␥ (1 ng/ml) for 3 h, 3) HMEC cells were treated with IL-6 (50 U/ml) for 1 h, or 4) HEMC cells were pretreated with IFN␥ (1 ng/ml) for 2 h and then with IL-6 (50 U/ml) for an additional hour.
RNA isolation and hybridization for microarray studies. Total RNA was isolated by using TRIzol (GIBCO; Carlsbad, CA) according to the manufacturer's instruction and stored at Ϫ80°C until use. Samples were sent to ServiceXS (Leiden, The Netherlands) for further processing. With the Agilent Bioanalyzer (lab on chip) the quality and integrity of the RNA samples were analyzed. The Illumina TotalPrep RNA Amplification kit (Ambion, art. no. AM-IL1791; Austin, TX) was used to synthesize biotine-labeled cRNA. Concentration of the labeled cRNA was measured by using the Nanodrop spectrophotometer. The amount of biotinylated cRNA that was hybridized onto the HumanRef-8 Expression BeadChip was 750 ng. In total 16 samples from 4 independent experiments (4 times 4) were used for RNA gene expression profiling. Two BeadChips were used, each one containing eight samples.
Gene expression analyses by qPCR. After total RNA was isolated using TRIzol (GIBCO), 1 g RNA was reverse transcribed (iScript cDNA synthesis Kit, Bio-RAD). Gene expression was assessed by real-time PCR (Applied Biosystems TaqMan Assays-on-Demand Gene Expression Products) using predesigned SOCS1, SOCS3, GAPDH, and 18S primers on the Applied Biosystems, 7900 HT Fast Real-Time PCR System. The amount of target gene in each subject was normalized to endogenous controls 18S (⌬CT). Gene expression is expressed as means (2 Ϫ⌬CT ϫ 100) Ϯ SD of at least six independent experiments.
Statistical data analysis. Results are expressed as means Ϯ SD. Data were compared by a one-way ANOVA and the Student-Newman-Keuls post hoc test, when appropriate. If data were not distributed normally we used Kruskal-Wallis ANOVA on ranks and Dunn's post hoc test. All statistical tests were performed with SigmaStat (version 3.5, Systat Software); P Ͻ 0.05 was considered to be significant.
Microarray analyses. We developed software for the analysis of the raw bead data (T4Illumina). Briefly, the program first tested for each gene identifier whether there were beads that were outliers. Individual beads were excluded if the signal intensity was greater than median intensity ϩ 2 ϫ median absolute deviation or less than median intensity Ϫ2 ϫ median absolute deviation. Next, the mean intensity was calculated for each gene and compared with the mean intensity of the negative controls. If the variance was not different between these means, a regular unpaired T-test was performed. If the variance was different, a T-test was performed for samples with unequal variance. The output of the program is 1) a quality control file, 2) a list with mean intensities per gene identifier, and 3) a similar list, but with added P values for the comparison to the negative controls. The mean intensities of all samples in all four groups were Log2 SVT normalized using FlexArray (http://genomequebec.mcgill.ca/FlexArray/) and a CyberT test performed for each relevant comparison. The normalized data were then read by a second routine of T4Illumina. For each group, it was determined whether the average of each gene intensity of the group was different from the average negative controls in that same group (P Ͻ 0.05 was considered significant). A comparison using Cyber T-test between two samples was only performed on a specific gene, if one of the groups showed an average gene intensity larger than the negative controls (P Ͻ 0.05 was considered significant). Data of all groups was put together in one file (if one of the averages per gene was higher than the negative control) and subjected to hierarchical cluster analysis using Expression Profiler (EBI). To identify the genes modulated by IL-6, IFN␥, or IFN␥ pretreatment ϩ IL-6, intensity values of gene expression from four independent replicates were combined for each group and ratios of IL-6 versus control, IFN␥ versus control, and IFN␥-pretreatment ϩ IL-6 versus control were generated (P Ͻ 0.05 was considered significant). Gene expression data has been submitted to NCBI Gene Expression Omnibus (dataset submitted to GEO; accession number GSE19082).
RESULTS

IFN␥ activated STAT1 and STAT3, and induced SOCS3 protein in a time-dependent fashion in endothelial cells.
Treatment of endothelial cells with IFN␥ resulted in both STAT1 and STAT3 phosphorylation in a time-dependent fashion (Fig. 1A) . STAT1 phosphorylation was already detectable after 15 min and reached its maximum after 30 min of exposure to 1 ng/ml IFN␥. STAT1 phosphorylation decreased after 1 h, but it was still detectable at 6 h. STAT3 phosphorylation upon exposure to IFN␥ appeared within 15 min, but it was shortlived and decreased to control levels after 1 h. IFN␥ did not affect total amounts of STAT1 and STAT3 protein at these time points.
We also measured SOCS3 protein expression, which was significantly increased after 1 h and strongly induced after 2 h of IFN␥ treatment and decreased after this. Increased SOCS3 protein was accompanied by fast reduction of phosphorylated STAT3. This suggests a regulatory role for SOCS3 in IFN␥-mediated STAT3 activation in endothelial cells.
IL-6 activated STAT3 and induced SOCS3 protein in endothelial cells in a time-and concentration-dependent fashion.
In contrast to IFN␥, IL-6 treatment of endothelial cells only phosphorylated STAT3 (Fig. 1B) . IL-6-induced STAT3 acti- http://ajpcell.physiology.org/ vation peaked at 30 min and rapidly decreased at later time points. As expected IL-6 stimulation of endothelial cells resulted in increased SOCS3 protein (Fig. 1B) , which increased after 30 min of treatment and reached its peak within 1 h. This correlated with decreased STAT3 phosphorylation. After 4 h, SOCS3 protein decreased, followed by a slight increase in STAT3 activation. Collectively this points to the importance of SOCS3 in regulating IL-6-induced STAT3 signaling in endothelial cells in vitro.
IFN␥ inhibits IL-6-induced STAT3 phosphorylation. Because IFN␥ was able to increase SOCS3 expression in endothelial cells, the possibility of IFN␥ to inhibit IL-6-induced STAT3 signaling was then studied. Indeed, pretreatment of endothelial cells with IFN␥ significantly decreased IL-6-induced STAT3 phosphorylation (Fig. 2 , compare lanes 2 and 3 with 5 and 6) without affecting total amounts of STAT3. IFN␥-induced STAT1 phosphorylation did not change in the presence of IL-6 and neither did total STAT1 levels. As shown in Fig. 2 , IFN␥-mediated inhibition of IL-6-induced STAT3 phosphorylation was preceded by increased IFN␥-induced SOCS3 protein expression (lane 4).
Inhibition of IL-6-induced STAT3 activation by IFN␥ is SOCS3 dependent. To obtain further evidence for a role of SOCS3 in IFN␥-mediated inhibition of IL-6 signaling, we first tested whether the effect of IFN␥ on IL-6-induced STAT3 activation was related to de novo gene or protein induction. Thus endothelial cells were costimulated with IFN␥ and IL-6 for 30 min. This reversed the inhibitory effect of IFN␥ on IL-6-induced STAT3 activation (Fig. 3A, compare lane 2 with  4) . Furthermore, incubation of endothelial cells with actinomycin-D to inhibit gene transcription prevented the inhibitory effect of IFN␥ on IL-6-induced STAT3 activation ( Fig. 3B ; compare lane 2 with 4, and 6 with 8; the inhibitory effect of Fig. 3 . Inhibitory effect of IFN␥ on IL-6-induced STAT3 activation is dependent on de novo gene/proteins induction. HMEC were treated with IFN␥ (0 -1 ng/ml) and IL-6 (0 -50 U/ml) simultaneously for 30 min (A) or incubated with actinomycine-D (10 g/ml) for 15 min (B) before IFN␥ (0 -1 ng/ml) stimulation for 2 h and IL-6 (0 -50 U/ml) for additional 30 min. Cell lystes were prepared to study STAT activation by Western blot analysis. Data were analyzed by one way ANOVA /Student-Newman-Keuls method (A, and B,  lanes 1-4) , or by Kruskal-Wallis ANOVA On Ranks/Dunn's method (B; lanes [5] [6] [7] [8] . P Ͻ 0.05 considered significant. Act-D on SOCS gene expression was confirmed: data not shown). Finally, the inhibitory effect of IFN␥ on IL-6 signaling was also partially decreased in endothelial cells in which SOCS3 expression was knocked down using siRNA (Fig. 4 , compare lane 2 with 4, 6 with 8). This strongly suggests that IFN␥-induced SOCS3 expression is, at least partially, involved in the inhibition of IL-6-induced STAT3 activation in the presence of IFN␥.
Transcriptional responses in endothelial cells to IL-6 is limited compared with IFN␥.
To examine how IFN␥ pretreatment affected the response to IL-6 at a genome-wide level, and in particular whether distinct sets of IL-6 target genes could be identified that respond differently under these conditions, we performed expression profiling. First, we compared transcriptional responses of endothelial cells to IL-6 (1 h; based on the time course study) or IFN␥ (3 h; based on the duration of endothelial cells stimulation with IFN␥ in our system) alone, or after combined treatment (IFN␥ 3 h, IL-6 1 h) using microarrays. In contrast to IFN␥, IL-6 changed the expression of a relatively small number of genes in endothelial cells (821 vs. 170 respectively; Fig. 5 ). However, the additive or synergistic interactions between IL-6 and IFN␥ substantially increased the number of up-as well as down-regulated genes (Fig. 5) . As indicated in the Venn diagram (Fig. 5) , there are 1,485 genes regulated by IFN␥ ϩ IL-6. There is also an overlap between IL-6-and IFN␥-modulated genes; 30% of IL-6-regulated genes, are also modulated by IFN␥ (Fig. 5) . Table 1 shows the 10 maximally upregulated genes in response to IFN␥ and Table 2 shows this of IL-6. Nine of the 10 maximally IFN␥-upregulated genes shown in Table 1 were known IFN␥-target genes. Only eosinophil lysophospholipaselike (LOC400696) has not been reported previously as an IFN␥ target (Table 1) . Likewise, among the 10 highest IL-6-induced genes (Table 2) , most genes could be recognized as known IL-6 target genes including, suppressor of cytokine signaling 3 (SOCS3), pim1, Myc, and BCL3 (40) . Nuclear localized factor 2 (NLF2) has not been previously reported as an IL-6 (and IFN␥) target gene. While monocyte chemoattractant protein-1 (MCP-1) and NLF-2 were increased by both IL-6 and IFN␥, Myc was decreased by IFN␥.
IFN␥-pretreatment of HMEC cells differentially affected IL-6-regulated genes.
Then we aimed to identify how crosstalk between IFN␥/IL-6 could affect the downstream IL-6 target genes (Table 3) . We identified three groups of genes. The first group contained genes with reduced expression to IL-6 following IFN␥ pretreatment, including SOCS3, mitogenactivated protein 3 kinase 8 (MAP3K8), Myc, and inhibitor of DNA binding 1 (ID-1), basic helix-loop-helix domain containing, class B-2 (BHLHB2), sprouting homolog 1 (SPRY1), snail homolog 1 (SNAI1), angiopoietin-like 4 (ANGPTL4), axin-1 upregulated 1 (AXUD1), and immediate early response 3 (IER3). In accordance with SOCS3, these genes might represent STAT3-dependent IL-6 targets. In contrast, the expression of a second group of genes, including MCP-1, NLF2, zinc finger protein 36 (ZFP36), SOCS1, stanniocalcin 1 (STC1), activating transcription factor 3 (ATF3), and chemokine (C-X-C motif) ligand 2 (CXCL2), was increased under these conditions. Interestingly, we could also identify IFN␥ target genes that showed increased expression [e.g., CCL8, ISGF3G (IRF9), and CXCL11] in the presence of IL-6. The expression of SOCS1 and SOCS3 genes was additionally examined by real-time PCR (Fig. 6 ) and confirmed the microarray data.
DISCUSSION
IL-6 is involved in endothelial dysfunction and atherosclerosis and has pro-and anti-inflammatory properties. The antiinflammatory effects of IL-6 are dependent on STAT3 and are modulated by SOCS3. During inflammation IL-6 is often increased in the presence of other inflammatory factors, which can modulate IL-6 action in macrophages by upregulating SOCS3 expression (3, 19, 28) . Information about IL-6 signaling in endothelial cells is limited but could be particularly relevant for the development of endothelial dysfunction. The present study addressed the question of whether IFN␥ can modulate the pro-and anti-inflammatory actions of IL6 in a SOCS3-dependent manner in the endothelial cells.
Our results in endothelial cells showed that IFN␥ activated both STAT1 and STAT3. However, whereas STAT1 activation was long lasting, STAT3 activation was short lived. This latter was accompanied by increased SOCS3 protein levels, which led to rapid inhibition of IFN␥-induced STAT3 activation. This suggests a novel mechanism through which early induction of SOCS3 steers IFN␥ to signal through STAT1 by blocking the STAT3 pathway. We also observed that IFN␥ stimulation of endothelial cells resulted in the induction of a high number of genes, confirming that biological responses to IFN␥ are strongly regulated at the level of gene expression (31) . Most of the highly induced IFN␥-induced genes are known to be involved in the inhibition of proliferation and induction of apoptosis (e.g., GBP-1 and IRF1) (8, 10) or increased adhesiveness of immune cells to endothelial cells (e.g., CXCL10 and CXCL11) (24, 27, 39) . IFN␥ also strongly induced both SOCS1 and SOCS3 expression, which was confirmed by real-time PCR.
IL-6 on the other hand was only shown to activate STAT3, which was short lived and returned to normal levels after SOCS3 protein was elevated. This confirms the inhibitory effect of SOCS3 on IL-6-induced STAT3 activation in endothelial cells. Furthermore, IL-6 treatment of endothelial cells resulted in induction of only a limited number of genes, among which some were pro-inflammatory including MCP1, MAP3K8, CEBPD, and NLF2 (9, 15) . Other IL-6 target genes were anti-inflammatory and/or anti-proliferative as exemplified by ZFP36, Id-1, BCL3, and Myc (13, 25, 29, 37, 41, 46) . Furthermore, IL-6 strongly induced SOCS3 gene expression, which was confirmed by real-time PCR. Together these genes reflect the pleiotropic nature of IL-6 signaling in endothelial cells and correlate with the pro-and anti-inflammatory characteristics. Most reports regarding anti-inflammatory effects of IL-6 refer to its ability to decrease cytokine production by activated macrophages (1, 42) . This effect has been shown to be dependent on IL-6-induced STAT3 activation and is similar to the anti-inflammatory effect of IL-10, although weaker (28, 43) . The reason for the weaker anti-inflammatory response of IL-6 has been related to the higher sensitivity of IL-6-induced STAT3 activation to the inhibitory effects of SOCS3 (28) . This hypothesis has been confirmed by Yasukawa et al. (44) who showed that in the absence of SOCS3, IL-6 has more profound anti-inflammatory effects on macrophages, which was related to prolonged activation of STAT3. These observations point to the importance of STAT3 in transmitting the anti-inflammatory effects of IL-6 and the importance of SOCS3 in inhibiting STAT3 actions.
IFN␥-induced SOCS3 in endothelial cells allowed us to study whether SOCS3 could interfere in a cross-inhibitory fashion with IL-6 action. In the present study, indeed inhibitory effects of IFN␥ on IL-6-induced STAT3 activation (up to 47% reduction) were accompanied by increased SOCS3 protein expression. An IL-6 autoinhibitory effect could be ruled out because of two main reasons; 1) IL-6 does not induce significant amount of SOCS3 protein within 30 min (Fig. 1B) , 2) FN␥ inhibits IL-6-induced STAT3 activation, and consequently, this results in inhibition of SOCS3 expression by IL-6 because of STAT3-dependency.
Furthermore, the inhibitory effect of IFN␥ was related to de novo protein induction, because short-term costimulation of endothelial cells with IFN␥ and IL-6 (which would not allow de novo protein induction before IL-6 stimulation) did not show the inhibitory effect on IL-6-induced STAT3 activation. Moreover, inhibition of de novo gene and protein induction by Act-D completely abrogated the inhibitory effect of IFN␥ on IL-6-induced STAT3 activation. Finally, SOCS3 mRNA knockdown in endothelial cells using RNA interference partially reversed the inhibitory effect of IFN␥ on IL-6-induced STAT3 activation. Although this paper does not provide data regarding a reduction in SOCS3 gene or protein level in siRNA experiments, it provides indirect effect on the level of STAT3 activation. Furthermore, the SOCS3 siRNA observations are in line with the costimulation data (Fig. 3A) and the Act-D observations (Fig. 3B) and clearly indicate the involvement of SOCS3 as an underlying cause of IFN␥-induced inhibition of IL-6 signaling through STAT3. This is in agreement with previous observations in macrophages, in which inflammatory signals like IFN␥, LPS, IL-6, IL-10 are able to inhibit IL-6 signaling in a SOCS3-dependent manner (19) . On the other hand, also SOCS3-independent mechanisms have been described. For example, it was shown that LPS can inhibit IL-6-induced STAT3 activation independent of de novo gene transcription (12) . Similarly, phorbol 12-myristate 13-acetate (PMA) and ionomycin inhibits IL-6-induced STAT3 activation; again, this does not require new RNA or protein synthesis (32) . Although our results cannot rule out SOCS3-independent mechanisms, they provide strong evidence to suggest that in endothelial cells IFN␥-induced SOCS3 expression, at least partially, underlies the inhibition of IL-6 STAT3 signaling in the presence of IFN␥.
To examine how IFN␥ pretreatment affected the response to IL-6 at a genome-wide level and in particular whether distinct sets of IL-6 target genes could be identified that respond differently under these conditions, we performed expression profiling. Before entering a detailed discussion about the most relevant observations of the microarray analysis, it should be remarked that global assessments using hierarchical clustering and pathway analyses were performed, however, seemed to be too global to yield any useful insights.
At least three sets of genes were identified. The first group included IL-6 target genes that were inhibited in the presence of IFN␥ such as SOCS3, Id-1, Pim-1, MAP3K8, BHLHB2, and Myc. As the expression of these genes followed inhibition of STAT3 activation (under these conditions), it can be proposed that they represent STAT3 target genes. Indeed previous studies revealed the STAT3 dependency of Myc, SOCS3, and Pim1 (4, 13, 22) . In conjunction with our other results, this strongly suggests that the expression of IL-6 target genes that are STAT3 dependent is diminished in the presence of IFN␥ in a SOCS3-dependent manner. Since Id1, Pim-1, SOCS3, and Myc are also rapidly induced by IFN␥ in the absence of STAT1 (30, 31) , we suggest that the induction of these particular genes by IFN␥ is mediated by rapid activation of STAT3 independent of STAT1. The second group of genes shows an expression pattern like MCP-1. These genes are induced by both IL-6 and IFN␥, and their expression is further enhanced upon combined IFN␥ and IL-6 stimulation. Examples include MCP-1, NLF-2, ZFP36, and CXCL2. As the expression of these genes does not follow the pattern of IL-6-induced STAT3 activation in the presence of IFN␥, it could be speculated that these genes might be STAT3 independent. A comparative study in wild-type and STAT1
Ϫ/Ϫ cells indicated that MCP-1 can be induced in both cell types upon IFN␥ stimulation (31); characterizing MCP-1 as a STAT1-independent gene. Although, the STAT dependency or independency of the other genes in this class needs to be clarified, we suggest that the expression of these genes might not solely be STAT1 or STAT3 dependent and could imply the involvement of other transcription factor(s) in IL-6 signaling. This is also supported by the observation that the expression of these genes upon IFN␥ stimulation is much lower than STAT1-dependent target genes of IFN␥ such as IP-10 and IRF-1 (31) . With respect to NLF-2, it should be mentioned that it can be also induced by IL-1␤,and TNF-␣ in endothelial cells (9, 15) , possibly in a STAT-independent fashion.
The third group of genes consists of IFN␥ target genes that are increased in the presence of IL-6 and include CXCL11, CCL8, ISGF3G, ATF3, and SOCS1. The expression of CCL8, CXCL11, and SOCS1 have been demonstrated to be STAT1 dependent upon IFN␥ stimulation (23, 31) , suggesting that IL-6 might somehow potentiate the transcriptional activity of STAT1. Although, we could not demonstrate further activation of IFN␥-induced STAT1 activation upon IL-6 stimulation, this does not rule out the possibility that IL-6 could potentiate the transcriptional activity of STAT1. This is supported by the observation that STAT1 activation in endothelial cells was not concentration dependent upon 1-5 ng/ml IFN␥ (data not shown), suggesting that STAT1 is maximally activated even with 1 ng/ml IFN␥.
In summary, in endothelial cells IFN␥ inhibits STAT3-dependent IL-6 signaling by increasing SOCS3 expression. This leads to decreased expression of some predominantly anti-inflammatory or proliferative genes. In contrast, other IL-6 target genes of more pro-inflammatory nature are not inhibited but even increased. Thus, in endothelial cells, IFN␥ shifts IL-6 signaling in favor of a pro-inflammatory phenotype. These findings could be important in the context of endothelial dysfunction, in which the presence of SOCS3 could inhibit the anti-inflammatory and proliferative effects of IL-6 through STAT3. Conversely, pro-inflammatory and pro-apoptotic effects of IFN␥ could lead to endothelial cells apoptosis and damage, which together could represent a novel mechanism involved in endothelial dysfunction.
